1. Home
  2. TIPT vs CAPR Comparison

TIPT vs CAPR Comparison

Compare TIPT & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiptree Inc.

TIPT

Tiptree Inc.

HOLD

Current Price

$17.55

Market Cap

672.9M

Sector

Finance

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$9.00

Market Cap

584.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TIPT
CAPR
Founded
2007
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
672.9M
584.9M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
TIPT
CAPR
Price
$17.55
$9.00
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$44.63
AVG Volume (30 Days)
155.0K
5.9M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
1.40%
N/A
EPS Growth
N/A
N/A
EPS
0.34
N/A
Revenue
$488,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.31
P/E Ratio
$51.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.49
$2.96
52 Week High
$27.38
$40.37

Technical Indicators

Market Signals
Indicator
TIPT
CAPR
Relative Strength Index (RSI) 39.34 48.78
Support Level $17.32 $8.18
Resistance Level $18.72 $11.00
Average True Range (ATR) 0.29 0.69
MACD -0.09 0.22
Stochastic Oscillator 16.85 29.57

Price Performance

Historical Comparison
TIPT
CAPR

About TIPT Tiptree Inc.

Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: